Myome

What Myome does

MyOme is a privately held, Menlo Park, California-based clinical genomics company founded in 2017 that operates a CLIA-certified, CAP-accredited laboratory performing whole-genome sequencing and a Blended Genome-Exome assay to deliver both proactive screening and rare-disease diagnostic tests ordered through a Provider Portal and Patient Portal. Its proactive health portfolio combines Single-Gene Risk panels, a Medication Response pharmacogenomic screen covering 70+ medications, and an Integrated Polygenic Risk Score (iPRS™) family for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer; its diagnostic portfolio includes Rare Disease Exome, Rare Disease Genome, and Rare Disease Copy Number Analysis, with optional trio/duo configurations, family variant testing, and re-queryable whole-genome data. The core technical differentiator is the proprietary iPRS methodology, which integrates millions of genetic variants with clinical risk factors such as ASCVD Pooled Cohort Equations and Tyrer-Cuzick and applies continuous ancestry decomposition to deliver risk estimates validated across diverse and mixed-ancestry cohorts (140,000+ individuals for prostate cancer, 150,000+ for breast cancer).

Revenue is generated on a pay-as-you-go basis via multiple streams: per-test diagnostic fees (CPT-coded 81415/81416, 81425/81426, 81349) billed through insurance, institutional contracts, self-pay, or financial assistance; bundled Proactive Health and Proactive Health Plus screening packages (FSA/HSA eligible); channel revenue from an exclusive partnership with Natera for the Zenith whole-genome rare-disease portfolio leveraging Natera's nationwide EMR-integrated clinical network; B2B distribution through employer benefits marketplaces (Thatch/ICHRA, Collective Health's The Partner Collective, Novi Health) and the Proactive Health Network of concierge, executive health, and longevity clinics; and follow-on Family Variant Testing and re-requisitions billed per variant from existing whole-genome data. Go-to-market spans direct-to-patient self-pay, provider-led ordering, channel partners, and employer/benefits-led distribution, with event-driven scientific marketing at ACMG, ASHG, ASCO, and ACC. The company is venture-backed (Sequoia, Foresite, HCVP, Founders Fund, Norwest, Alexandria, SoftBank, Duquesne, Natera) and received a strategic investment from Illumina in December 2025 alongside the MyOme Proactive Health (MPH) clinical trial launching enrollment in 2026.

Name

Myome

Legal name

MyOme, Inc.

Website

https://myome.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

MyOme is a clinical genomics company that uses whole-genome sequencing and proprietary Integrated Polygenic Risk Scores (iPRS™) to deliver proactive screening and rare-disease diagnostic tests to patients, providers, employers, and concierge clinics through its CLIA-certified Menlo Park laboratory and channel partnerships including Natera.

Ownership category

akta.pro rank

Product category

Clinical Genomics / Genetic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Clinical whole genome sequencing
• Polygenic risk scores
• Rare disease diagnostics
• Pharmacogenomic testing
• Genetic counseling services

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Test Fees (Rare Disease Exome/Genome/CNV): Billed per test order with acceptable billing types including Insurance Coverage, Institutional, Self-Pay, and Financial Assistance (interest-free payment plans, income/family-based financial assistance, prompt-pay discounts). CPT-coded tests (e.g., 81415/81416 for exome, 81425/81426 for genome, 81349 for CNV).
2. Proactive Health Screening Tests (Single-Gene Risk, Medication Response, iPRS): Screening tests sold to providers and through employer/benefits channels; patients can use FSA/HSA for screening tests. Offered as bundled Proactive Health and Proactive Health Plus packages or standalone iPRS tests, with flexible payment options.
3. Channel Distribution Revenue via Natera (Zenith): Exclusive partnership with Natera for the Zenith whole-genome rare disease test portfolio; Natera leverages its nationwide EMR integration to scale distribution and MyOme participates in revenue from tests delivered through Natera's clinical network.
4. B2B Employer/Benefits Channel Revenue: Distribution via benefits marketplaces such as Thatch (ICHRA), Collective Health's The Partner Collective, and Novi Health, plus the Proactive Health Network of concierge/executive clinics, providing genomic testing embedded in employer health programs and clinic memberships.
5. Follow-up / Family Variant Testing Requisitions: Re-requisitions on existing whole-genome data and Family Variant Testing billed per variant tested (insurance or out-of-pocket); creates recurring engagement from the same patient/family without requiring a new sample.

Pricing tiers

Go-to-market motion6 records

Distribution channels6 records

Marketing channels7 records

Core offering

MyOme operates a clinical whole-genome sequencing platform that delivers proactive screening tests (Single-Gene Risk™, Medication Response™, and Integrated Polygenic Risk Score [iPRS™] tests for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer) and rare disease diagnostic tests (Rare Disease Genome, Exome, and Copy Number Analysis). All tests are processed at MyOme's CLIA-certified, CAP-accredited clinical laboratory in Menlo Park, CA, from a single patient sample, and are ordered through the MyOme Provider Portal or Patient Portal.

Product overview

Myome operates a unified clinical whole-genome testing platform that powers a portfolio of proactive screening and rare-disease diagnostic products ordered through the MyOme Provider Portal. The platform leverages 30x Whole Genome Sequencing (WGS) and Blended Genome-Exome Sequencing (BGE) to deliver the Proactive Health suite (Single-Gene Risk™, Medication Response™, and Integrated Polygenic Risk Score [iPRS™] tests for Coronary Artery Disease, Breast Cancer, Type 2 Diabetes, and Prostate Cancer) alongside the Diagnostic suite (Rare Disease Exome, Rare Disease Genome, and Rare Disease Copy Number Analysis), with Follow-up Testing (Requisitions and Family Variant Testing) extending insights from a single sample over time. The platform also underpins the MyOme Proactive Health Network for concierge and executive clinics, the Zenith™ rare-disease portfolio co-developed with Natera, and the MyOme Patient Portal for result access and education.

Differentiator

Problem solved

Functional benefit

Brands

• Proactive Health: MyOme's flagship portfolio of proactive genomic screening tests covering Single-Gene Risk, Medication Response, and Integrated Polygenic Risk Scores (iPRS) for coronary artery disease, breast cancer, type 2 diabetes, and prostate cancer.
• Integrated Polygenic Risk Score (iPRS)
• Proactive Health Network (PHN)

Products and services

• Proactive Health Test Suite
• Single-Gene Risk™
• Medication Response™
• Coronary Artery Disease iPRS™ (CAD iPRS)
• Breast Cancer iPRS™
• Type 2 Diabetes iPRS™ (T2D iPRS)
• Prostate Cancer iPRS™
• Rare Disease Exome Analysis
• Rare Disease Genome Analysis
• Rare Disease Copy Number Analysis
• Follow-up Testing (Requisitions and Family Variant Testing)
• Zenith™ Rare Disease Testing Portfolio (with Natera)

Quantifiable outcome

• Up to ~70% (T2D), ~60% (prostate cancer), and ~50% (CAD) of heritable disease risk can be detected as genetic markers by MyOme iPRS tests
• +8 more outcomes

Named customers14 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature7 records

Partnerships

Eleven partnerships are on record, tiered minor, flagship and core.

• Start Genetic / CureSHANKminorGTM or Marketing Partner · 25 July 2026MyOme is a supporting sponsor of the second annual Genetic Testing Action Day on July 25, 2026, an international awareness initiative operated by nonprofit CureSHANK and lead-sponsored by Illumina to raise awareness of genetic testing for rare diseases and developmental disabilities.
• NateraflagshipStrategic or Co-development Partner · 12 March 2026Exclusive strategic partnership to develop and commercialize the Zenith whole-genome sequencing portfolio for rare disease diagnosis. The test uses long-read sequencing and was presented at the 2026 ACMG Annual Clinical Genetics Meeting. Natera leverages its nationwide EMR integration footprint to scale distribution of MyOme's genome-first diagnostic across the US, while also investing in MyOme's broader financing round.
• ThatchcoreGTM or Marketing Partner · 15 December 2025Embedded MyOme's genomics-based proactive health reports into Thatch's Personalized Benefits Marketplace, providing employer members easier access to predictive, preventative health insights. First genomics solution offered through Thatch's ICHRA platform.
• IlluminaflagshipStrategic or Co-development Partner · 11 December 2025Collaboration plus strategic investment from Illumina to support MyOme's Proactive Health (MPH) Trial, a large-scale prospective study starting enrollment in 2026 that will evaluate whole-genome sequencing combined with AI-integrated risk models for early detection of common, chronic conditions, cancers, and rare diseases. Illumina's sequencing technology roadmap (NovaSeq X) and continued backing are intended to accelerate MyOme's rare disease testing innovation and expand its commercially available products.
• Ms.MedicinecoreStrategic or Co-development Partner · 3 December 2025Strategic partnership to integrate MyOme's Proactive Health portfolio (monogenic disease screening, pharmacogenomic insights, polygenic risk scores) into Ms.Medicine's national network of women's health and concierge primary care practices. Tests delivered via Nest Genomics' clinical decision-support platform.
• Mayo Clinic PlatformcoreStrategic or Co-development Partner · 12 August 2025MyOme joined the Mayo Clinic Platform_Accelerate cohort, an initiative supporting healthcare innovators to validate and scale AI-based solutions using rich, de-identified clinical data sets to advance preventative care.
• Collective Health (The Partner Collective)coreGTM or Marketing Partner · 7 May 2025MyOme joined The Partner Collective by Collective Health — a digital health partner hub that helps employers, brokers, and consultants discover and engage with innovative benefits offerings — to expand access to MyOme's whole-genome based products.
• Novi HealthcoreGTM or Marketing Partner · 30 January 2025Collaboration to bring whole-genome sequencing, polygenic risk modeling, and personalized genetic counseling to employees as part of Novi Health's workplace health benefits, enabling participants to take preventative action against common and hereditary conditions.
• Southern ResearchcoreStrategic or Co-development Partner · 14 October 2024Multi-party initiative with Broad Clinical Labs and MyOme to bring MyOme's industry-leading clinical risk assessments free of charge to patients and providers in Alabama, empowering underserved communities with personalized genetic insights and potential life-saving interventions.
• Broad Clinical LabscoreTechnology or IntegrationSequencing technology partnership: Broad Clinical Labs deploys MyOme's bioinformatics and analysis pipeline on top of its advanced whole-genome sequencing technologies to deliver MyOme's individual risk assessments to clinics and patients.
• Arboretum BiominorGTM or Marketing PartnerQuoted partner endorsing MyOme's role in addressing long-standing biases in medicine and advancing precision medicine for diverse populations.

Scale indicators11 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Ambry Genetics: Ambry Genetics (a Konica Minolta company) provides clinical exome and genome sequencing with a focus on rare-disease diagnosis and hereditary cancer. It competes directly with MyOme in the rare-disease diagnostic market and shares the CPT-coded clinical lab business model.
• Human Longevity Inc. Human Longevity offers whole-genome sequencing combined with advanced imaging and AI-driven preventive health assessments to executive and longevity-focused members. It is a direct peer to MyOme's Proactive Health Network and high-end proactive whole-genome testing positioning.
• Color Health: Color Health is a clinical genetics platform offering hereditary cancer screening, whole-genome sequencing, and employer-sponsored preventive genomics programs. It competes head-to-head with MyOme in the same employer/benefits and provider channels for preventive genetic testing.
• GeneDx: GeneDx is a clinical genomics company focused on rare-disease exome and genome sequencing for pediatric and neurological indications. It is a direct peer in MyOme's diagnostic rare-disease exome/genome/CNV offering, competing for the same ordering physicians and CPT-coded reimbursement.
• Invitae: Invitae is a clinical genetic testing company providing hereditary cancer, rare-disease, and reproductive health testing through providers and biopharma. It is a comparable peer across MyOme's diagnostic portfolio despite Invitae's recent financial restructuring.
• 23andMe: 23andMe is a consumer genetic testing company offering ancestry, trait, and health risk reports including polygenic risk scores. It is comparable in the direct-to-consumer and preventive health testing space and competes for similar consumer mindshare on genetic risk.
• Helix: Helix operates a clinical whole-genome sequencing platform that powers both rare-disease diagnostic and population-health applications via partner health systems. Like MyOme, Helix sells a re-queryable WGS backbone to providers, health systems, and consumer channels.

Broad incumbents

• Tempus: Tempus is an AI-driven precision medicine company combining multi-omics data with clinical records for oncology and beyond. It is a broader incumbent in genomics-enabled clinical decision support, with overlapping AI + clinical-data positioning versus MyOme's AI-integrated iPRS pipeline.
• Natera: Natera is a large, publicly traded cell-free DNA and reproductive health testing company that is also MyOme's exclusive Zenith distribution partner and investor. It is comparable in genetic testing scale and serves as both a partner and adjacent incumbent across reproductive, oncology, and rare-disease genomics.

Emerging players

• Genomic Prediction: Genomic Prediction develops and commercializes polygenic risk scores for disease risk assessment. It overlaps with MyOme's iPRS portfolio on the polygenic methodology but with a narrower set of conditions and a more research-oriented go-to-market.

Market position

Strengths6 records

Weaknesses6 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/myomeinc
• LinkedInlinkedin.com/company/myome

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myome